logo
Google's AI CEO explains why he's not interested in taking LSD in his quest to understand 'the nature of reality'

Google's AI CEO explains why he's not interested in taking LSD in his quest to understand 'the nature of reality'

Demis Hassabis prefers gaming over acid trips.
The Google DeepMind CEO said he's never taken LSD and doesn't want to. In a recent interview with Wired's Steven Levy, the AI boss was asked about his pursuit of understanding the "nature of reality," as his X bio states.
More specifically, Hassabis was asked if acid had ever helped him get a glimpse of the nature of reality. The short answer is no.
"I didn't do it like that," Hassabis said. "I just did it through my gaming and reading a hell of a lot when I was a kid, both science fiction and science."
Hassabis set out as a child to understand the universe better, and the quest is ongoing. He's hoping AI and, eventually, artificial general intelligence will help reach his goal. While some tech leaders have talked about using psychedelics, Hassabis said he's "too worried about the effects on the brain."
"I've sort of finely tuned my mind to work in this way," he said. "I need it for where I'm going."
Google DeepMind is the research lab behind the company's AI projects, including chatbot Gemini. Hassabis is leading Google's charge toward the AI race's holy grail — AGI.
Google DeepMind didn't immediately respond to a request for comment from Business Insider.
Over the years, Silicon Valley has embraced the use of psychedelics, such as microdosing to improve productivity or going on ayahuasca retreats. Some investors have banked on their popularity, backing psychedelic startups that are seeking to turn the drugs into medical treatments or expand the industry in other ways.
However, that's not a green light to take acid or magic mushrooms on the clock. In 2021, CEO Justin Zhu, cofounder and CEO of a startup called Iterable, said he was fired for microdosing LSD before a meeting. He hoped it would improve his focus, he said.
Some of Hassabis's tech peers have been open about using LSD as established bosses or as college students. Microsoft cofounder Bill Gates, for example, took acid for the first time as a teenager, according to his memoir, " Source Code: My Beginnings."
For Gates, dropping acid was exhilarating at first and a "cosmic" experience when he did it again. However, he ended up thinking his brain could delete his memories like a computer.
"That would be one of the last times I would do LSD," Gates said.
It didn't have that effect on Apple cofounder Steve Jobs, who told his biographer, Walter Isaacson, that it was "a profound experience, one of the most important things in my life."
OpenAI's Sam Altman has also spoken positively about his experience with psychedelics. Although he didn't specify exactly what drug he took, he said it changed him from a "very anxious, unhappy person" to "calm."
"If you had told me that, like, one weekend-long retreat in Mexico was going to significantly change that, I would have said absolutely not," Altman said. "And it really did."
For Hassabis, he's seeking other ways to find answers to life's deepest questions.
"We don't know what the nature of time is, or consciousness and reality," he told Wired. "I don't understand why people don't think about them more. I mean, this is staring us in the face."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Acclaimed Indie Rock Band Exits Spotify With Bold Political Statement
Acclaimed Indie Rock Band Exits Spotify With Bold Political Statement

Yahoo

time23 minutes ago

  • Yahoo

Acclaimed Indie Rock Band Exits Spotify With Bold Political Statement

Acclaimed Indie Rock Band Exits Spotify With Bold Political Statement originally appeared on Parade. Spotify is the most popular music streaming platform in the world, so it takes some guts for an act to stand up against it and pull their music off the service, but that's exactly what acclaimed indie rock act Deerhoof has done. The band recently took to its official Instagram account to announce the move. 🎬 SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox 🎬 'We're taking Deerhoof off Spotify,' the band posted on June 30. '' uses $700 million of his Spotify fortune to become chairman of AI battle tech company' was not a headline we enjoyed reading this week. We don't want our music killing people. We don't want our success being tied to AI battle tec,' it continued. Deerhoof recently released its 20th album, Noble and Godlike Ruin, to widespread acclaim and continues to be a successful touring act. In a statement provided by the band's press representatives, Deerhoof offered further explanation. 'We are privileged that it was a pretty easy decision for us. Spotify only pays a pittance anyway, and we earn a lot more from touring. But we also understand that other artists and labels do rely on Spotify for a bigger chunk of their income, and don't judge those who can't make the same move in the short term,' the band added. 'AI battle tech is clearly emerging as the hot new big ticket item for the super-rich. It's increasingly clear that the military and police exist primarily as the security detail for the billionaire class. The more of the killing you can get computers to do, the better your bottom line.'Deerhoof isn't the first act to cross swords with Spotify. famously pulled his music off of the streaming service in 2022 in protest over Spotify's decision to distribute 's podcast. Young accused Rogan of spreading misinformation about COVID-19. However, Young returned to the service two years later after Rogan's podcast became available on other platforms, including Apple, Amazon, Qobuz and Tidal. "I cannot leave all those services like I did Spotify, because my music would have no streaming outlet to music lovers at all, I have returned,' Young wrote on his website at the time. Acclaimed Indie Rock Band Exits Spotify With Bold Political Statement first appeared on Parade on Jul 1, 2025 This story was originally reported by Parade on Jul 1, 2025, where it first appeared.

New AI tool is better than doctors at diagnosing complicated medical issues, Microsoft says
New AI tool is better than doctors at diagnosing complicated medical issues, Microsoft says

Yahoo

time39 minutes ago

  • Yahoo

New AI tool is better than doctors at diagnosing complicated medical issues, Microsoft says

Microsoft said it is one step closer to 'medical superintelligence' after a new artificial intelligence (AI) tool beat doctors at diagnosing complex medical problems. Tech giants are racing to develop superintelligence, which refers to an AI system that exceeds human intellectual abilities in every way – and they're promising to use it to upend healthcare systems around the world. For the latest experiment, Microsoft tested an AI diagnostic system against 21 experienced physicians, using real-world case studies from 304 patients that were published in the New England Journal of Medicine, a leading medical journal. The AI tool correctly diagnosed up to 85.5 per cent of cases – roughly four times more than the group of doctors from the United Kingdom and the United States, who had between five and 20 years of experience. Related As AI reshapes patient care, human nurses are pushing back against its creeping influence The model was also cheaper than human doctors, ordering fewer scans and tests to reach the correct diagnosis, the analysis found. Microsoft said the findings indicate that AI models can reason through complex diagnostic problems that stump physicians, who specialise in their fields but are not experts in every aspect of medicine. However, AI 'can blend both breadth and depth of expertise, demonstrating clinical reasoning capabilities that, across many aspects of clinical reasoning, exceed those of any individual physician,' Microsoft executives said in a press release. 'This kind of reasoning has the potential to reshape healthcare'. Microsoft does not see AI replacing doctors anytime soon, saying the tools will instead help physicians automate some routine tasks, personalise patients' treatment, and speed up diagnoses. Microsoft's AI system made diagnoses by mimicking a doctor's process of collecting a patient's details, ordering tests, and eventually narrowing down a medical diagnosis. A 'gatekeeper agent' had information from the patient case studies. It interacted with a 'diagnostic orchestrator' that asked questions and ordered tests, receiving results from the real-world workups. Related Is AI going to steal your job? Probably not, new study finds The company tested the system with leading AI models, including GPT, Llama, Claude, Gemini, Grok, and DeepSeek. OpenAI's o3 model, which is integrated into ChatGPT, correctly solved 85.5 per cent of the patient cases, compared to an average of 20 per cent among the group of 21 experienced doctors. The researchers published their findings online as a preprint article, meaning it has not yet been peer-reviewed. Microsoft also acknowledged some key limitations, notably that the AI tool has only been tested for complicated health problems, not more common, everyday issues. Related AI to shape EU health policymaking without new rules The panel of doctors also worked without access to their colleagues, textbooks, or other tools that they might typically use when making diagnoses. 'This was done to enable a fair comparison to raw human performance,' Microsoft said. The company called for more real-world evidence on AI's potential in health clinics, and said it will 'rigorously test and validate these approaches' before making them more widely available.

Why Intel Growth Story May Be Hitting a Wall
Why Intel Growth Story May Be Hitting a Wall

Yahoo

time39 minutes ago

  • Yahoo

Why Intel Growth Story May Be Hitting a Wall

June 26 - Intel (NASDAQ:INTC) could be heading into tougher terrain as geopolitical tensions and new export rules weigh heavily on the chipmaker's China-reliant business. While the company continues to promote its AI and foundry ambitions under new CEO Lip-Bu Tan, its fundamental outlook remains fragile amid a shifting regulatory landscape. Taiwan's recent move to include Huawei and SMIC on its Strategic High-Tech Commodities Entity List marks another potential blow. The change effectively blocks the export of semiconductor products to firms without a special license, disrupting Intel's access to Huawei, a key PC customer in China. Huawei's MateBook lineup, powered by Intel Core Ultra processors, saw growing momentum in 2024, but future deliveries may now face delays or compliance hurdles. Warning! GuruFocus has detected 7 Warning Signs with INTC. Intel's dependence on China, where it derived about 29% of its 2024 revenue, primarily through its Client Computing Group (NASDAQ:CCG), exposes it to tightening U.S. and allied export controls. The CCG unit, which accounted for more than 60% of Intel's consolidated sales in Q1, remains a core earnings driver. But any shift in trade policy that restricts sales of mainstream PC chips, even indirectly, could weigh on results. The chip maker is also dealing with wider execution issues. Its combativeness into AI servers through the Gaudi platform lags behind the shark competitor Nvidia (NASDAQ:NVDA), and the enhanced suspension of Falcon Shores chips highlights execution remnants. Meanwhile, the capital requirements of Intel Foundry are high, and it is not completely clear how the solution will be adopted by external customers long-term. The action by Taiwan in July which evoked this move was an attempt to restrict its exports as part of the U.S attempt to restrict the Chinese access to advanced technologies. All these developments echo previous shocks, including the mid-2024 cancellation of Intel export licenses to Huawei that resulted in 30% plunges when its stock failed to meet results in China. There is relatively no response in the market yet, as Intel shares remained around $20 in spite of such accumulating risks. But analysts caution that this complacency will not be sustained. Having weak underlying principles, poor performance of its AI roadmap, and growing headwinds within the regulatory environment, the Intel stock might be subjected to the continuation of its decline. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store